Undecimal Bio
AI-enabled platform for targeted delivery of siRNA therapeutics.
Undecimal Bio is a biotech & life sciences company based in Cambridge, GB, founded in 2026. It has raised $17.9 million in disclosed funding. Its latest round was a Seed of €16 million in October 2026.
Overview
No overview yet. It is written from sources once there are enough of them.
Funding
Total disclosed: $17.9M across 1 round. Computed only from sourced rounds.
| Date | Company | Amount | Stage | Lead | Other investors | Sector | Sources |
|---|---|---|---|---|---|---|---|
| €16M | Seed | 4BIO Capital, IQ Capital | Verve Ventures +4 | Biotech & Life Sciences | 1 |
- Undecimal Bio€16M
Led by 4BIO Capital, IQ Capital · with Verve Ventures, +4
Investors
Questions and answers
What does Undecimal Bio do?
AI-enabled platform for targeted delivery of siRNA therapeutics.
How much has Undecimal Bio raised?
Undecimal Bio has raised $17.9 million in disclosed funding across 1 round tracked by OSH.
Who has invested in Undecimal Bio?
Investors in Undecimal Bio include 4BIO Capital, IQ Capital, Verve Ventures, Harel Tech, Entree Capital and 2 more.
When and where was Undecimal Bio founded?
Undecimal Bio was founded in 2026 and is based in Cambridge, GB.
Timeline
Founded
Sources
- 1.Undecimal Bio lands €16 million to develop targeted RNA medicines beyond the liver — EU-Startups, Oct 13, 2026